Life-changing Aussie cure for peanut allergies step closer to release
Researchers from Melbourne's Murdoch Children's Research Institute (MCRI) have received 6 million U.S. dollars and are in negotiations to receive a further $5.3 million to take to market their world-first treatment for the most common cause of violent anaphylactic reactions.
"Peanut allergies are a massive problem and this is an innovative approach. There's a clear path to a marketable product here that could have tremendous impact globally," Paul Kelly, managing director of OneVentures which invested the 6 million U.S. dollars, told News Limited on Thursday.
"It's a potential cure. We'll put a very commercial focus on the work to make it a (United States) Food and Drug Administration (FDA) approved product in due course, and then a marketed pharmaceutical product around the world."
An anaphylactic reaction can be triggered by any antigen, most commonly bee stings and various foods, and can be lethal.
The treatment involves administering small amounts of peanut flour to children with peanut allergies, building up to two grams or the equivalent of six peanuts, along with daily doses of probiotic Lactobacillus rhamnosus.
Following 18 months of the treatment, up to 82 percent of children in trials showed an improved tolerance to peanuts five weeks after finishing the treatment. ■